Wei Xie

1233 Validation and Clinical Assessment of BCMA and CD19 CAR-T by DxFLEX 13-Color Flow Cytometer and Incorporating Immunoregulatory Markers

Adam Martin, Smith Kungwankiattichai, Yun Sawyer, Sa Wang et autres

us, th (code pays fourni par la source)

1190 Acute Erythroid Leukemia Clonally Evolved from Myeloid Neoplasms

Megan J. Fitzpatrick, Ji Yuan, Daniel Akuma, Andrew W. Allbee et autres

us (code pays fourni par la source)

Plasmacytoid dendritic cell clusters are associated with poor prognosis in chronic myelomonocytic leukemia

Deepika Kumar, Wei Cheng, Lisa Y. Lin, Philipp W. Raess et autres

us, ca, Égypte (code pays fourni par la source)

Site accessibility-driven CRISPR/Cas13a activation for amplification-free RNA biosensing

Zhaleh Asadi Fakhr, Wei Xie, Su Zeng, Sheng Cai

cn (code pays fourni par la source)

Lipo-MIT-based bridging therapy enables effective CAR-T treatment in high-risk relapsed or refractory B-cell lymphoma

Yun Jin Kang, Danying Liao, Wei Xie, Lin Liu et autres

Abstract Background: Chimeric antigen receptor (CAR)-T cell therapy has significantly improved outcomes for relapsed or refractory (R/R) B-cell lymphoma. However, high tumor burden and bulky disease are risk factors of poor prognosis and severe adverse effects (AEs). Bridging therapy (BT) aims to …

hk, cn (code pays fourni par la source)

Bendamustine combined with fludarabine/cyclophosphamide as a enhanced lymphodepletion regimen demonstrates favorable efficacy and safety in CAR-T therapy for extranodal/bulky R/R B-cell lymphoma

Cong Hui Lu, Danying Liao, Lin Liu, Wei Xie et autres

Abstract Introduction： Bulky disease has been identified as an independent predictor of poor outcomes following CAR-T therapy. Although lymphodepletion (LD) critically affects CAR-T cell functionality and treatment response, its clinical significance remains undervalued, with no established protocols for standardized regimens. While bendamustine …

hk, cn (code pays fourni par la source)

Clinical outcomes and novel therapeutic strategies in adult patients with MLL-rearranged acute lymphoblastic leukemia: A monocentric retrospective analysis

Lin Liu, Yinqiang Zhang, W J Wang, Wei Xie et autres

Abstract Introduction: Adults with MLL-rearranged b-cell acute lymphoblastic leukemia (MLL-r B-ALL) face dismal outcomes due to intrinsic chemo-resistance (historical median OS <12 months). While the efficacy of blinatumomab and CAR-T therapy has been established in relapsed/refractory B-ALL, clinical studies in adult patients …

hk, cn (code pays fourni par la source)

Supplemental Figure 1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Overall survival based on (A) NPM1 mutation status, (B) FLT3-ITD mutation status within NPM1 mutated cases only, (C) IDH1 mutation status, and (D) IDH2 mutation status. Reported p-values utilized the cox model Wald test.

Supplemental Figure 6 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Surface expression of CD14, CD64, and CD11b in cases by genetic mutation compared to a wild-type reference cohort within the subset of patients with centralized quantitative MFC performed (n = 144). * indicates p < 0.05, ** indicates p < 0.01, *** …

Supplemental Figure 2 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Overall survival based on monocytic differentiation status censored at HCT for patients within specific mutation subgroups including (A) combined RAS pathway mutations (N/KRAS and PTPN11), and isolated mutations in (B) FLT3-ITD, (C) NRAS, (D) KRAS, (E) PTPN11, and (F) TP53. Patients with …

Supplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Overall survival in the subgroup of patients not receiving allogeneic cell transplantation (HCT) based on (A) monocytic vs. non-monocytic differentiation, (B) monocytic differentiation and NPM1 mutation status, (C) in the subgroup of patients with RAS pathway and FLT3-ITD mutations (K/NRAS, PTPN11, FLT3-ITD) …

Supplemental FIgure 5 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Overall survival within the US cohort (n = 279) based on the presence of signaling pathway mutations including (A) NRAS, (B) KRAS, (C) PTPN11, (D) BRAF, (E) NF1, and (F) WT1. Reported p-values utilized the cox model Wald test.